These findings would argue towards a cautious use and further translation of such immunomodulatory approaches for use in patients with increased susceptibility to infections, such as stroke patients; therefore, more specific approaches that block specific pathways leading to subacute immune exhaustion rather than also inhibiting potential effector functions such as IL‐1β might be more promising for future development in stroke patients. The gene discussed is IL1B; the disease is infection.